Skip to main content

Table 1 Clinical and tumor characteristics

From: Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers

  BRCA1 n(%) BRCA2
n(%)
BRCAX n(%) All familial
n(%)
Age     
≤ 50 years 25 (89%) 15 (56%) 24 (61%) 64 (68%)
> 50 years 3 (11%) 12 (44%) 15 (39%) 30 (32%)
Tumor size     
< 20 mm 20 (71%) 13 (52%) 16 (47%) 49 (56%)
> 20 mm 8 (29%) 12 (48%) 18 (53%) 38 (44%)
Unknown 0 2 5 7
Nodal status     
Negative 26 (93%) 19 (70%) 25 (64%) 70 (74%)
Positive 2 (7%) 8 (30%) 14 (36%) 24 (26%)
Unknown 0 0 0 0
Grade     
I 0 1 (4%) 2 (6%) 3 (4%)
II 2 (9%) 10 (44%) 8 (24%) 20 (25%)
III 21 (93%) 12 (52%) 23 (70%) 56 (71%)
Unknown 5 4 6 15
ERα     
Negative 23 (85%) 5 (21%) 11 (32%) 39 (46%)
Positive 4 (15%) 19 (79%) 23 (68%) 46 (54%)
Unknown 1 3 5 9
PgR     
Negative 23 (85%) 9 (38%) 16 (47%) 48 (56%)
Positive 4 (15%) 15 (62%) 18 (53%) 37 (44%)
Unknown 1 3 5 9
HER2 status     
Negative 26 (100%) 22 (100%) 28 (85%) 76 (94%)
Positive 0 0 5 (15%) 5 (6%)
Unknown 2 5 6 13
Endocrine therapy     
Not given 22 (96%) 16 (76%) 21 (64%) 59 (77%)
Given 1 (4%) 5 (24%) 12 (36%) 18 (23%)
Unknown 5 6 6 17
Chemotherapy     
Not given 8 (30%) 15 (60%) 13 (39%) 16 (42%)
Given 19 (70%) 10 (40%) 20 (61%) 49 (58%)
Unknown 1 2 6 9
  1. n = 94.